FDA approves Humira for juvenile arthritis

WASHINGTON The Food and Drug Administration’s division of Anesthesia, Analgesia and Rheumatology Products has approved Abbott Laboratories’ drug, Humira, as a treatment for juvenile idiopathic arthritis.

The strengths available will be 20 mg/0.4 ml and 40 mg/0.8 ml in a single-dose prefilled syringe, and 40 mg/0.8 ml in a single-use prefilled Humira pen.

Humira had worldwide sales of $3.06 billion in 2007, according to Abbott Laboratories.